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This paper summarizes pathological changes that affect microglial cells in the human brain during aging and in
aging-related neurodegenerative diseases, primarily Alzheimer’s disease (AD). It also provides examples of microglial
changes that have been observed in laboratory animals during aging and in some experimentally induced lesions
and disease models. Dissimilarities and similarities between humans and rodents are discussed in an attempt to
generate a current understanding of microglial pathology and its significance during aging and in the pathogenesis
of Alzheimer dementia (AD). The identification of dystrophic (senescent) microglia has created an ostensible conflict
with prior work claiming a role for activated microglia and neuroinflammation during normal aging and in AD, and
this has raised a basic question: does the brain’s immune system become hyperactive (inflamed) or does it become
weakened (senescent) in elderly and demented people, and what is the impact on neuronal function and cognition?
Here we strive to reconcile these seemingly contradictory notions by arguing that both low-grade neuroinflammation
and microglial senescence are the result of aging-associated free radical injury. Both processes are damaging for
microglia as they synergistically exhaust this essential cell population to the point where the brain’s immune system is
effete and unable to support neuronal function.
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The idea of “diseased microglia” represents a recent con-
ceptual development in neuropathology that was first
raised in the context of Creutzfeldt-Jakob disease [1].
Diseased microglia are different from activated micro-
glia, in that they are incapacitated cells whereas activated
microglia are cells capably responding to injury. Micro-
glial disability and dysfunction have now captured the
imagination of neuroscientists made apparent by a num-
ber of excellent recent reviews with different perspec-
tives on the subject [2-6]. Following the conceptual
introduction of diseased microglia by v. Eitzen et al. [1],
additional clues about the existence of unhealthy micro-
glia came from immunohistochemical studies describing
abnormal morphological features of microglial cells in
the aged human brain [7], termed microglial dystrophy
and thought to reflect microglial senescent degeneration.
The microglial dysfunction hypothesis of Alzheimer’s dis-
ease (AD) claiming that neurofibrillary degeneration is the
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unless otherwise stated.the same year [8]. Microglial morphology has been and
continues to be of interest to neuroscientists due to its
ever-changing nature and the initial morphological as-
sessments suggesting pathological dysfunction have
been strengthened by recent genetic discoveries, which
are discussed in the above mentioned reviews. It seems
a milestone has been reached in terms of a renewed ap-
preciation of the importance of diminutive microglial
cells whose main function in normal brain is to make
sure neurons are well protected and connected [9-12].
As the idea of microglial dysfunction gains momentum
and its implications for improved understanding of de-
mentia pathogenesis are being realized, we consider it im-
portant to summarize the current state of the art from a
neuropathological perspective, as well as to discuss poten-
tial causes and consequences of microglial degeneration.
In this paper, we focus on microglial cell morphology
and phenotype as seen by immunohistochemical staining
of brain sections. Morphological plasticity is a character-
istic feature of microglia that is evident even in the static
images of traditional microscopy, as shown here. Mod-
ern microscopy methods allowing live cell imaging have
confirmed what has long been suspected from cell cul-
ture studies [13], namely that microglia are on the movetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ably time to abandon the term “resting microglia”,
although it may still serve the purpose of providing an
antonym to “activated microglia”. It remains a challenge
to translate morphological plasticity into more detailed
functional plasticity and to further investigate the mean-
ing of altered morphological appearances, such as hyper-
trophy and dystrophy. While it is known, in general, that
hypertrophy is associated with activation, i.e. increased
metabolic and phagocytic activity in energized microglia,
and that dystrophy is associated with senescent degener-
ation in burned-out microglia, there are many stages in
between these two extremes as both activation and sen-
escence are progressive processes with many gradations
[3,16]. Microglial activation ensues rapidly following
most perturbations of CNS homeostasis, and the inten-
sity and extent to which it occurs is commensurate with
the severity of the disturbance. For example, minimally
activated microglia are also known as primed microglia
and they have been described mostly in experimental
mouse model systems [17-19], and to a lesser extent in
human brain [20]. In contrast, maximally activated
microglia appear as rounded brain macrophages that
are also referred to as amoeboid microglia [21,22].
Senescent changes in microglia may develop gradually
over decades during human aging and likely occur as a
consequence of multiple influences on the CNS micro-
environment, notably free radical-mediated oxidative
damage. However, microglial pathology can also occur as
a result of sudden extreme stress, as suggested by findings
from experimental animals. A good approach towards un-
derstanding functional changes that occur in microglia as
they undergo morphological transformations in human
brain is through characterization of their immunophe-
notype, which can be quite heterogeneous due to up-
and down-regulation of multiple proteins and receptors
[23,24]. Microglia harbor a large assortment of intracel-
lular and surface antigens and there exists an arsenal of
antibodies directed against various microglial antigens,
some of which can be linked to specific functions [22].
As the number of microglia-binding antibodies continues
to grow, it is likely that these reagents will facilitate an
ever more refined in situ assessment of microglial pheno-
types which in conjunction with morphological changes
will provide information about cell function and dysfunc-
tion in a variety of disease states. In situ description and
evaluation of microglia in human brain in terms of their
morphology and phenotype is essential for elucidating the
role these cells play in neurodegenerative disease patho-
genesis. Human histopathology is also important for
establishing relevance and represents the first line of in-
vestigation for neurodegenerative conditions. Together
with human genetic studies, as well as experimental
transgenic or other animal or cell culture models ofdisease addressing molecular mechanisms, true insights
into disease pathogenesis can be gained.
Microglial activation – is it pathological?
The currently widespread opinion that activated micro-
glia can be both beneficial and detrimental leaves open
the possibility that microglial activation is harmful under
certain conditions, and destructive microglial neurotox-
icity as a possible factor in neurodegenerative disease
has been discussed on numerous prior occasions (for re-
views see [5,25-27]). However, both resting and activated
microglia perform beneficial neuron-supporting func-
tions and they exert harmful effects only if they become
senescent, diseased, or die unable to perform their nor-
mal supportive roles. Microglial activation has been
described as a natural consequence to CNS injury in
countless, acute experimental situation since the days of
del Rio-Hortega [28] revealing how the brain responds
to injury and engages in wound healing. The purportedly
detrimental effects exerted by activated microglia in the
context of chronic neuroinflammation are inferred from
studies showing neurotoxic effects of rodent microglia
in vitro under artificial conditions. Neither the time
scales nor the microenvironment created in vitro are
representative of human brain [29], and while simplified
in vitro systems may show what microglia are theoretic-
ally capable of doing when stimulated to the maximal
extent possible, these results are not validated by human
neuropathology and they cannot address the complexities
of neurodegenerative disease pathogenesis with direct
relevance. A major discrepancy between microglial activa-
tion in vitro and in vivo is that in vitro experiments use
the proverbial sledgehammer method (LPS or similar) to
achieve maximal microglial stimulation in vitro, producing
maximal and readily measurable effects, while at the same
time it is recognized that the intensity of microglial activa-
tion in the normally aged and AD brain is consistent with
only minimal, low-level neuroinflammation [30-32]. To
equate such low-intensity microglial activation in human
brain with artificially produced high-intensity microglial
neurotoxicity in vitro constitutes a flaw in scientific
reasoning explained possibly by immature judgment or
premature ambition.
Microglial pathology in the aged brain
It is currently thought that chronic, low-level inflamma-
tion is associated with major degenerative diseases of
aging including those affecting the CNS [30,33]. Histo-
pathological studies suggesting that microglial activation
occurs with normal brain aging have contributed towards
this notion by showing increased microglial expression
of interleukin-1α and histocompatibility antigens (HLA-
DR) in humans [16,34-36], seemingly consistent with
observations in experimental animals showing increased
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class II antigens and upregulation of interleukin-1 on
acutely activated microglia and macrophages in a variety
of brain lesions [37-42]. Animal studies have also dem-
onstrated increased expression of MHC class II antigens
on microglia with aging, as well as morphological and
phenotypic transition to a more macrophage-like ap-
pearance [43-47]. Together with literature describing
fluctuations and increases in pro-inflammatory cyto-
kines during aging [18,48], the notion that chronic low-
level neuroinflammation accompanies brain aging is
thus firmly established. However, what is missing from
this conception is the inciting stimulus, that is, a defini-
tive cause of aging-associated chronic neuroinflamma-
tion remains unidentified. This stands in contrast to
other aging-related chronic, non-autoimmune inflamma-
tory conditions outside the CNS which usually have an
identifiable cause. For example, in osteoarthritis there is
loss/breakdown of articular cartilage which results in bone
damage, which in turn elicits a chronic inflammatory reac-
tion, underscoring the point that in order for inflamma-
tion to occur there must be damage or injury. Thus, if
brain aging causes low-level chronic inflammation it is im-
perative to understand the reasons for it.
It has been hypothesized that free radical damage in
the aging brain causes inflammation [18] but free radical
damage in neurons is subtle and non-specific, and there-
fore difficult to demonstrate histopathologically in nor-
mal human brain [49]. Nevertheless, assuming the free
radical theory of aging [50] is correct, free radical injury
occurs inevitably in aerobic organisms as a consequence
of life-long oxygen exposure at all levels producing oxi-
dized nucleic acids and proteins, damaged (senescent)
cells and tissues, which is what ultimately accounts for
the development of most aging-related diseases. It there-
fore makes sense that there would be a chronic low-level
inflammatory reaction because low-grade inflammation
is the predicted tissue response to subtle and gradually
developing CNS injury regardless of its cause. Put an-
other way, both chronic low-level inflammation and
microglial senescence are indirect and direct results, re-
spectively, of free radical injury associated with aging
(Figure 1). Importantly, the mild reactive gliosis (neuro-
inflammation) that occurs presumably as a result of free
radical injury is not an aggressive, neurotoxic type of re-
sponse and is detrimental only in the sense that it may
over time contribute towards development of senescence
and dysfunction. The recent demonstration by Raj et al.
[17] that DNA damage in a mouse model of genotoxic
stress causes mild microglial activation (priming) offers
clear support for the idea that free radical injury, which
often produces DNA damage, elicits low-level neuroin-
flammation. In addition, the fact that some measures of
aging-related, low-grade neuroinflammation can beattenuated by caloric restriction [47,51] also supports
the idea that neuroinflammation is due to free radical
damage, since lowered food intake is associated with de-
creased metabolic activity and concomitantly decreased
free radical production [50].
Regarding the microglial changes that occur during
aging, these can be seen as being consistent with both
mild activation and with senescence. While a rapidly
changing immunophenotype and dramatic morpho-
logical transformations are part of high-intensity micro-
glial activation after acute CNS lesions, such changes
occur only gradually during aging reflecting slowly pro-
gressive evolution of a senescent morphology and
phenotype, which is similar in its manifestation to low-
grade activation described in models of mild CNS injury
[52-54]. Microglial secretion of cytokines changes more
dramatically during acute, severe injury situation than it
does in less severe scenarios [55], and there are aging-
associated changes in microglial cytokine production
[56-58] which are consistent with the idea that microglia
develop a senescence-associated secretory phenotype
(SASP). Although thus far the notion of SASP has been
discussed in terms of non-CNS cell senescence and
tumor suppression rather than in a microglial context
[59,60], current understanding of microglial secretory
activity during aging and the fact that microglioma is an
exceedingly rare tumor [61] are compatible with the
SASP concept.
Microglial mitosis, which is part of microglial activa-
tion in acute injury situations when there is a sudden de-
mand for more cells to restore homeostasis, is absent or
minimal during normal aging when such impromptu de-
mands do not occur. However, when acute CNS injuries
happen in aged animals the ability of microglia to divide
is unimpaired and even greater than in young animals
[62] showing that microglial mitotic potential remains
robust in the aged rodent brain. In contrast, replicative
senescence (reduced mitotic activity) occurs when there
is repetitive CNS injury forcing microglia to undergo re-
peated bouts of mitosis over the course of one year [63].
Microglial mitosis is difficult to measure reliably during
aging in human post-mortem brain, and the most direct
evidence for microglial senescence has come from mor-
phological studies. The recognition of microglial dys-
trophy has provided an indication of microglial
senescence in the aged human brain [7]. With aging an
increasing proportion of microglial cells display abnor-
mal morphological features, such as shortened, gnarled,
beaded, or fragmented cytoplasmic processes, as well as
loss of fine ramifications and formation of spheroidal
swellings, changes that are designated collectively as
microglial dystrophy (Figure 2). Microglial dystrophy re-
flects the abnormal morphology of senescent microglia
because the number of dystrophic microglia increases
Figure 1 Microglial senescence may be a key event in aging and Alzheimer’s disease. Free radical injury occurs naturally during aging
affecting both microglia and neurons. It contributes to microglial senescence directly by causing oxidative injury in microglia, and indirectly by
causing oxidative injury in neurons which elicits a low-level inflammatory response. The latter causes chronic stress to microglia contributing to
exhaustion and senescence. If normal aging is exacerbated by acute injuries eliciting intense inflammation, this may accelerate naturally occurring
microglial senescence.
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gradually: during early stages microglia develop spher-
oidal swellings of their processes that can progress to
beading and eventually fragmentation leaving pinched–
off segments of microglial cytoplasm separated from the
perinuclear soma. Depending on how far senescent de-
generation has progressed, fragmentation of the micro-
glial cytoplasm (cytorrhexis) may be partial or it may
involve the entire cytoplasm leaving multiple fragments
that in some cases still delineate the cells’ contours, or
in the most advanced case of disintegration are widely
scattered about (Figure 3). Interestingly, the microglial
cell nucleus undergoes little structural change during
this cytoplasmic degeneration and can sometimes be
seen in one of the many fragments surrounded by a
small rim of perinuclear cytoplasm. Microglial dystrophy
may also reveal itself in the form of atrophic, gnarled, or
stripped down cytoplasmic processes where fine arbori-
zations have gone missing, similar to what has been ob-
served in senescent neurons [64].
The difficulty of interpreting microglial morphology and
phenotype in human brain
Histopathological studies of microglia can be a valuable
diagnostic aid to neuropathologists, a fact that was already
recognized many decades ago by del Rio-Hortega, who
wrote: “It is sufficient to find the microglial alterations to
recognize the areas more deeply affected by the disease”
[65]. Histological examination of microglia also providesan opportunity for research because the diversity and he-
terogeneity of microglial morphology that can be observed
in well-stained sections of human brain, particularly with
Iba1 antibody, is remarkable and stands in contrast to ro-
dents where microglial morphology is rather uniform.
Morphological heterogeneity of microglia in humans can
be explained in part by the principle that microglia repre-
sent a stable and enduring cell population with low turn-
over rates, a current notion that has resulted from a rather
turbulent series of experiments in mice which occurred in
the space of more than two decades: initially the bone
marrow chimera studies of Hickey and Kimura [66]
claimed a bone-marrow origin of microglia, but subse-
quent DNA labeling studies suggested stability and persist-
ence of the microglial population [67]. The latter notion
was then overturned again by a new set of bone marrow
chimera studies inferring substantial replacement of
microglia by bone-marrow-derived precursors [68]. How-
ever, later experiments demonstrated that irradiation used
to create chimeras causes brain damage and hence an in-
flux of the bone-marrow derived precursors [69]. The
current view is that microglia derive from primitive yolk-
sac macrophages in a Myb-independent manner [70,71].
They are thus genetically different from blood-derived
mononuclear cells and their population seems to depend
on life-long self-renewal, which renders them susceptible
to replicative senescence.
Therefore, this most current notion of microglial sta-
bility combined with the longevity of humans, complex
Figure 2 Dystrophic microglia have many guises and can be stained with different antibodies. A, B Iba1 (red) and CD68 (green) double
immunohistochemical staining of dystrophic microglia in AD brain, as seen by 3-D confocal microscopy. Note fragmentation of cytoplasmic
processes and punctate CD68 labeling indicating intracellular location of lysosomal antigen. C-E, anti-HLA-DR antigen immunohistochemistry
(LN-3 antibody) shows dystrophic spheroid formation (C), atrophic deramified processes (D), and formation of microglial aggregate with
spheroids (E). F, ferritin-positive fragmented microglia. G, Iba1-positive dystrophic microglia with beaded, fragmenting processes and spheroids.
All images taken in cerebral cortex of AD subjects. Scale bars: 10 μm (A, B), 20 μm (C, D, G), 40 μm (E, F).
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verse human lifestyles, diets, habits of drug consumption
(both medicinal and recreational), latent infections,
injuries, and systemic diseases, as well as subtle brain
pathologies all of which may influence microglial behav-
ior creates a tremendously heterogeneous picture that is
reflected in the diverse microglial phenotypes encoun-
tered. This morphological heterogeneity of the microglial
population can make it difficult to differentiate between
non-activated, activated, and senescent (diseased) micro-
glia since some features may not be unequivocal, andthus morphological assessments are best combined with
immunophenotypic ones employing several microglial
markers to characterize cells.
A key issue is the reliable identification of and distinc-
tion between activated and diseased microglia, because
this ultimately provides clues about the cells’ (dys) func-
tional activities in any given region of interest. Since there
are no single histochemical markers to facilitate simple
differentiation multiple markers together with morpho-
logical assessments comprise a conclusive evaluation. Both
microglial activation and microglial dystrophy are defined
Figure 3 Schematic representation of cytorrhexis development. Ramified cells (1) develop spheroidal swellings (2), which progress to
beading and partial fragmentation of processes (3), which progresses to complete fragmentation while still maintaining cell contours (4),
eventually ending up as scattered fragments (5). Note that the cell nucleus remains intact throughout.
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[7,72]. With the advent of Iba1 antibody [73] a robust re-
agent has been made available that is resistant to variable
tissue fixation and processing protocols and will label all
morphological variants of microglia, thereby eliminating
largely the problem of inconsistent staining outcomes seen
previously with other antibodies under different tissue
processing conditions. Iba1 staining allows for excellent,
unequivocal morphological differentiation of resting, acti-
vated, phagocytic and dystrophic microglia (Figure 4).
Staining for HLA-DR antigens is of particular interest
since many antibodies directed against these antigens are
available and have been used widely to identify activated
microglia in human brain, based primarily on the fact that
studies in experimental CNS lesions had shown an up-
regulation of major histocompatibility complex (MHC)Figure 4 Different functional states of microglia can be defined morp
with which they explore their surrounding microenvironment. B, activated
build-up and increased metabolic activity. C, phagocytic microglia often ap
characteristically display beaded, twisted or fragmented processes. Humanantigens by acutely activated microglia [38-40]. However,
HLA-DR antigens are present on large numbers of non-
activated, ramified microglia in normal human brain
[74,75] and HLA-DR expression seems to be affected not
only by fixation but by a variety of factors, including gen-
der, age, genotype, and possibly others [34,76]. In some rat
strains a high level of constitutive MHC II expression has
been reported [77] suggesting that MHC expression could
vary also with ethnicity in humans, but this has not been
studied. One recent study shows no difference in HLA-
DR expression between AD and control subjects [78].
Overall the specific meaning of HLA-DR expression re-
mains unknown and its use for demonstrating activated
microglia limited. Its use as a neuroinflammation marker
is questionable for reasons already mentioned: widespread
expression in normal CNS and high individual variability.hologically. A, ramified microglia exhibit highly branched processes
microglia retract processes and become enlarged due to organelle
pear as rounded brain macrophages. D, dystrophic microglia most
cerebral cortex stained with Iba1 antibody. Bar = 20 μm.
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Neuroimmunological differences between rodent and hu-
man microglia were discussed recently [26], and we would
like to not only support the perspectives conveyed by
these authors but add to them by pointing out that
microglial dystrophy as it appears with aging in human
brain is not seen in the aged rodent brain. Dystrophy is
part of the aforementioned morphological heterogeneity
of human microglia and the fact that it is absent in la-
boratory rodents speaks to the vast differences in life-
span and environment between rodents and humans.
Brain aging happens differently in a short-lived animal
raised in a nearly pathogen-free and unchanging environ-
ment (incl. a never changing diet) than in a human being
where numerous environmental influences can play a role.
The one thing common to rodents and men is the air they
breathe and the oxygen in it, and it would be safe to say
that free radical-mediated oxidative injury plays a role in
both rodent and human aging. Microglial cells in rodents
do undergo aging-related changes and in light of the con-
stancy of their environment these changes are likely to be
caused exclusively by the free radical damage that occurs
over time. In the terms of grade-school arithmetic, aging-
related changes in rodent microglia represent the least
common denominator. Vaughan and Peters provided the
first and most comprehensive account of these changes
using both light and electron microscopy, and in essence
their findings show an increase in cell size due to accu-
mulation of dense inclusions closely resembling lipofuscin
deposits [54]. Given the unchanging, sanitary, and uncon-
taminated lives of laboratory rodents it would be reaso-
nable to assume that occurrence of these lipofuscin
deposits is purely a consequence of time passed and is
therefore not pathological. Lipofuscin deposits can also be
found in human microglia [79], but in addition human
cells show those morphological abnormalities that we call
microglial dystrophy which may well be a reflection of on-
going pathology. With reference to earlier work [80], one
can thus speak of normal and pathological aging also in
terms of microglia (Figure 5).
In the same vein, the term neuroinflammation when
applied to rodents in the context of normal aging is in-
appropriate as inflammation is inherently tied to injury
and pathology, and it would be a stretch (in our minds)
to call normal aging a disease. Perhaps more compelling
is to point out that these purely aging-related alterations
in rodent microglia are not associated with neuronal
pathology, unlike in humans where microglial dystrophy
and neurofibrillary degeneration appear to be linked.
Microglial pathology and neurodegeneration
Neurofibrillary degeneration (NFD), or tau pathology, and
synapse loss offer the best neuropathological correlates of
cognitive impairment and dementia in AD [81-85], and itwill be important to elucidate the role that microglial cells
play in the development of AD-type neurodegeneration.
For quite some time now it has been hypothesized that
neurodegenerative changes in AD are caused by patho-
logically activated microglia thought of as autoaggressive
immune effector cells exerting neurotoxic actions. Ac-
cording to the amyloid cascade/neuroinflammation hy-
pothesis, deposits of amyloid-beta (Aβ) protein incite
chronic microglial activation and with it a detrimental
neuroinflammatory reaction characterized by elevated
production of proinflammatory cytokines, neurotoxins,
and free radicals that cause neurodegeneration [86,87].
However, the evidence in support of this theory is at best
indirect and at worst directly opposed to the idea, and
some of the caveats associated with it have already been
discussed, i.e. the large discrepancy in the intensity of
microglial activation between in vitro and in vivo studies,
the difficulty of reliable identification of activated micro-
glia in human brain, and the fact that neuroinflammation
in AD is quite mild and therefore unlikely to be destructive
[88]. Additional concerns are raised by findings showing
that, a) tau pathology occurs in the absence of Aβ deposits
and in the absence of microglial activation [89-91]; b) ad-
ministration of anti-inflammatory drugs does not slow or
reverse tau pathology or cognitive decline [92-94]; c) tau
pathology is not initiated or exacerbated by presence of se-
vere neuroinflammation [95]; d) tau pathology does not
occur in transgenic animals overexpressing amyloid pre-
cursor protein despite extensive Aβ deposition and associ-
ated microglial activation [96-98]. For these reasons and
others discussed in this paper activated microglia are un-
likely suspects in the causation of neuronal pathology as-
sociated with AD. Instead it is more likely that
degenerating (dystrophic) microglia are linked to NFD be-
cause they increase in prevalence as NFD becomes more
widespread, they are co-localized with neurofibrillary tan-
gles and senile plaques, and their occurrence precedes the
spread of tau pathology [91,99]. The link between micro-
glial and neuronal degeneration is in line also with the fun-
damental idea of glial-neuronal interdependency, namely,
that neuronal well-being is dependent on presence of
healthy glial cells. The thought that microglial degener-
ation is critically important in AD pathogenesis is sup-
ported by additional observations showing high incidences
of microglial apoptosis in AD brain [100-102].
Damaged neurons undergoing NFD are not “obvious
stimuli for inflammation” as previously thought [48] since
there is little evidence for glial reactions to NFD or the
phagocytic removal of neurofibrillary tangles in the AD
brain. In fact there is little evidence of any phagocytic
activity in cases of advanced AD or DS where morpho-
logically intact microglia or brain macrophages are diffi-
cult to discern (Figure 6). Because microglial and neuronal
pathology are coincident in AD brain it is tempting to
Figure 5 Histopathological differences in microglial aging between laboratory rodents and humans provide a foundation for normal
and pathological aging. Mice and rats experience only normal aging due to their short life spans and controlled environment, whereas humans
who live much longer lives are exposed to diverse environmental influences and lifestyles, including diets, physical and mental activities, drugs,
pollutants, comorbidities and infections, all of which may affect the rates at which microglial senescence (dystrophy) occurs, indicated by
different trajectories of dashed red lines. As dystrophy occurs to varying degrees there is a decline in microglial neuroprotection and with that
neurofibrillary degeneration (NFD) increases at variable rates in different individuals.
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there is no obvious reactive response of microglia to NFD
the most likely scenario is that microglial dysfunction and
death are a prelude to subsequent neuronal demise. Both
microglial dystrophy and NFD are considered to be patho-
logical events in humans where they can be detected quite
early in some instances albeit without apparent neuro-
logical problems [7,89-91]. As NFD and microglial dys-
trophy become more widespread over time they
eventually reach critical levels and become symptomatic.
The progression of both processes is likely affected to
varying degrees by external influences (Figure 5) and both
dystrophy and NFD appear to be restricted largely to the
human species and do not occur spontaneously even in
aged laboratory rodents, where the main aging-related ef-
fect on both neurons and microglia is accumulation of
lipofuscin.
The idea that detrimental microglial activation also
contributes to the degeneration of neurons in the sub-
stantia nigra in Parkinson’s disease (PD) is firmly embed-
ded in the literature yet much of it is speculative and
extrapolated from animal and cell culture models
[103-107]. In a thoughtfully delivered discussion, Croi-
sier et al. state unequivocally that “there is no evidence
that microglia initiate neurodegeneration” [108], and it
would thus be fair to say that microglial involvement in
PD remains a controversial and unresolved issue[109,110]. One aspect that is clear is the ability of micro-
glia to phagocytize neuronal debris [108,111,112], pro-
viding a plausible explanation for presence of activated
microglia/macrophages in the substantia nigra of nor-
mally aged humans [113], and certainly why microglial
activation is prominent in animal models of PD where
lesions and toxins are used to induce death of nigral
neurons acutely [114-119]. With regard to the character-
istic Lewy body pathology of PD, which is absent in most
PD animal models, studies in humans have shown a lack
of microglial activation in the vicinity of Lewy bodies
[120,121], a finding which we have been able to corrob-
orate (Figure 7). However, these findings contrast with
those of others who do claim that activated microglia
are associated with Lewy bodies and Lewy neurites and
contribute neurotoxically to degeneration of nigral neu-
rons [122,123]. It has not yet been determined whether
or not presence of Lewy pathology can be correlated
with appearance of microglial dystrophy.
Microglia and amyloid-beta protein in human brain
Current understanding of the relationship between
microglia and amyloid-beta protein (Aβ), as well as the
many questions that have arisen from it, have been dis-
cussed in detail recently [3], and in the interest of non-
redundancy we focus the current discussion on one par-
ticular aspect of that relationship that has not yet
Figure 6 Widespread dystrophy and absence of brain
macrophages are evident in Down syndrome brain. Iba1-stained
section of cerebral cortex from a subject with Down syndrome with
Braak stage VI neurodegeneration. Normal microglial morphology is
barely discernable in only few cells and the field is mostly occupied
by microglial membrane fragments of varying shapes and sizes.
Scale bar: 100 μm.
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rimental effects on microglia. It is generally thought that
Aβ activates microglia causing them to exert neurotoxic
effects, which is a key component of the amyloid cascade
theory of AD. However, and with reference to Figure 1
in [3] showing activated microglia gathered in an Aβ
plaque in a transgenic mouse model, it is apparent that
any activating effect of Aβ, as evidenced by the micro-
glial hypertrophy shown in this vivid image, is limited to
cells located in the immediate vicinity and along the rim
of the Aβ deposit. The activating effect of Aβ is highly
localized affecting only those microglia that are in directFigure 7 Absence of activated microglia near neurons with
Lewy bodies. Double-label immunostaining for microglia (Iba1,
brown) and α-synuclein (black) in a subject with PD, stage 5. Section
of neocortex shows Lewy bodies in cortical neurons (arrows)
surrounded by normal, ramified microglia.physical contact with Aβ, whereas microglia located in
the neuropil between Aβ deposits are ramified and non-
activated, a pattern that is also seen in human brain
[124]. The image shown in Figure 1 [3] is strongly rem-
iniscent of a foreign body reaction, where microglia are
trying to remove Aβ but are unable to do so. It may well
be an example of so-called frustrated phagocytosis [87],
but the consequences of this frustration may be different
than thought. Traditional thinking has it that microglia
activated and frustrated by contact with non-degradable
amyloid plaques upregulate toxic inflammatory media-
tors that cause neurodegeneration [87], but this is clearly
not the case in the transgenic mouse model (APPPS1)
shown [3] where NFD does not occur. If NFD were
present, one would expect to find it close to where acti-
vated microglia are located. A different picture also
emerges if one takes a closer look at microglia in and
around Aβ deposits in humans, where microglia appear
as either ramified cells in diffuse (early) plaques or as
dystrophic cells in neuritic (late) plaques [91] (Figure 8).
In advanced plaques of the compact, dense-core, or
neuritic type frustrated microglia trying to remove amyl-
oid plaques become dystrophic and they can be seen to
undergo cytorrhexis and burn out. As shown in Figure 8,
dense-core plaques, also known as burned-out plaques
[20], have a dense core that contains burned-out microglia
and thus although “burned-out plaque” was used before
anybody knew about burned-out (dystrophic) microglia, it
turns out that it was a very appropriate term to use. More-
over, there are examples of previously published images
showing ostensibly activated microglia in and around
amyloid deposits where the cells’ morphology is rather
more dystrophic than activated, e.g. [124-126], and the
ultrastructure of microglia within amyloid plaques in
humans is consistent with senescence revealing lipofuscin
deposits, vacuolization of the cytoplasm, and swollen
endoplasmic reticulum [109,124,127]. All this raises ques-
tions about whether plaque-associated microglia even be-
come activated or how long they may remain activated
before they degenerate. Head et al. [126] have shown that
oxidized Aβ is found within microglia that are ostensibly
activated, but are really dystrophic according to the
morphology shown, and that oxidized Aβ is present in
98% of cored plaques, which supports the observations
shown in Figure 8. Oxidation of Aβ may be the result of
aging-related free radical damage, as it is for many other
proteins and nucleic acids, or it may occur because of
microglial actions as discussed in [126], but whatever the
mechanisms it seems clear that oxidation of Aβ acceler-
ates Aβ aggregation and fibrillization [128,129]. Since dys-
trophic microglia are associated with advanced plaques
containing mostly insoluble fibrillar amyloid, the conclu-
sion that amyloid has a detrimental or toxic effect on
microglia is quite evident. Detrimental effects on
Figure 8 Ramified and dystrophic microglia are associated with amyloid-beta protein deposits. Double-label immunohistochemistry for
Aβ protein (brown reaction product; 4G8 antibody) and microglia (black reaction product; Iba1 antibody) in human cerebral cortex. A, diffuse Aβ
deposits are colocalized with ramified, non-activated microglia, B, as Aβ deposits become more compact microglia begin to show signs of
dystrophy (arrow points to early fragmentation and spheroid formation). C, D show several advanced dense-core plaques where the dense core
is comprised of dystrophic microglial fragments (white arrows). Note multiple microglial fragments in the immediate vicinty of Aβ deposits.
Bar = 50 μm.
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lated human plaques have been described in vitro
[130,131]. We therefore conclude that amyloid deposits
represent an endogenous influence, in addition to the
various external factors already mentioned (Figure 5),
that contributes towards microglial degeneration. Ag-
gregated Aβ in amyloid plaques together with other po-
tentially toxic plaque components, notably iron
[132-135], are likely to contribute pathologically to-
wards dementia development by being toxic to micro-
glia and promoting microglial degeneration which then
leads to neurofibrillary degeneration.
Causes of microglial pathology
Other than plain cellular senescence, our current under-
standing of mechanisms that cause or aggravate microglial
dystrophy and degeneration is in its infancy. As shown in
Figure 5, pure non-pathological aging as it occurs in la-
boratory rodents is not sufficient to trigger dystrophic
changes, and other factors related to human longevity, di-
versity of living, and the complexity of human genetics are
likely to play a role [136]. Notwithstanding this uncer-
tainty an important clue about potential triggers of micro-
glial degeneration was provided by observations showing
that many dystrophic microglia are positive for the iron
storage protein, ferritin, and that such cells are prevalentin AD brain [137,138]. Iron dyshomeostasis has long been
implicated in the pathogenesis of neurodegeneration, but
there is incomplete understanding of the specific mecha-
nisms that may underlie the involvement of iron
[26,139-142]. Most authors see the detrimental role of iron
in its potential to cause oxidative stress more or less dir-
ectly to neurons thereby contributing to neurodegenera-
tion. In light of the foregoing discussion about microglial
pathology and the importance of neuronal-glial depend-
ency, one might rethink the role of iron and consider the
possibility that the effects of iron-mediated oxidative stress
may not be directed primarily or exclusively towards neu-
rons but to microglial cells as well. Presence of free iron in
the brain represents a potentially dangerous situation,
which is why iron is sequestered through iron-binding
proteins, such as ferritin. In situations where there is sud-
den entry of iron into the CNS parenchyma, for example
during intracerebral hemorrhages, it is of critical import-
ance that the iron be sequestered rapidly and effectively,
and this is a critical function of microglial first responders.
Experimental studies in animals have shown that when
microhemorrhages occur or when there is CNS trauma,
microglia not only become positive for ferritin they also
become dystrophic [143,144]. The strong correlation
between ferritin positivity and dystrophy, reflected in find-
ings from both human brains as well as from experimental
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hazardous activity that can cause damage to microglial
cells. It is also an important mechanism by which micro-
glia can protect neurons from oxidative damage, that is,
microglia take the brunt of iron-mediated oxidative stress
and deflect it away from neurons. Compared to neurons,
microglia are relatively expendable cells since there is re-
newal capacity from within the CNS (mitosis) as well as
from bone marrow [66,68,145-149], and one might draw
the analogy to the game of chess where pawns are sacri-
ficed to save the more valuable pieces. In terms of neuro-
degenerative disease pathogenesis where stroke and/or
microbleeds are clearly risk factors [150-152], one can see
how such vascular events can contribute to microglial de-
generation and thus presumably to neurodegeneration.
The situation may be aggravated further by the fact that
microglial renewal capacity in aged subjects is likely to be
reduced [153].
Cytorrhexis represents the most striking example of
microglial dystrophy and is indicative of an advanced, near-
terminal state of cytoplasmic deterioration. Mouse models
of AD do not show presence of fragmented microglia, al-
though a recent study demonstrates other, more subtle al-
terations in microglial morphology amounting to cells
being less ramified and possessing fewer branches and fine
processes [154]. Cytoplasmic fragmentation of microglial
cells has been reported in one transgenic model, the
huGFAP-CCL2 transgenic mouse where microglial func-
tions are impaired and cells fail to undergo amoeboid trans-
formation and instead show cytoplasmic fragmentation in
cortical slice preparations [155]. We have described exten-
sive microglial cytorrhexis to occur in the SOD1G93A trans-
genic rat, an animal model of motor neuron disease [156].
In this model, microglial fragmentation occurs late in the
course of the disease after a long-lasting neuroinflammatory
reaction and during the period of maximal motor neuron
degeneration, thus supporting the coincidental and possibly
linked development of microglial and neuronal degener-
ation. The fact that microglial cytorrhexis occurs after
prolonged microglial activation during symptomatic
motor neuron disease supports the idea that long-lasting
microglial activation leads to immune exhaustion and
microglial burn-out (Figure 9). However, microglial abnor-
malities are present at all stages of motoneuron disease in
the SOD1G93A rat where they are evident as cellular aggre-
gations and fusions. Most conspicuous among the latter is
the formation of Langhans-type multinucleated giant cells
(MNGCs), which is a highly unusual phenomenon to ob-
serve in rat brain. In humans, MNGCs are almost always
found in disease states associated with immune suppres-
sion, notably HIV encephalitis but also lymphomas and
tuberculous meningitis, and are thought to occur via
fusion of virus-infected microglia [157]. MNGCs represent
a spectacular example of microglial pathology wherediseased cells lose their normal contact inhibition and
melt together into a non-functional syncytium. Underscor-
ing the idea of microglial dysfunction is the fact that in
SOD1G93A transgenic rats MNGCs were coincident with
another bizarre event in rat brain, namely the presence of
bacillus bacteria (Figure 10). This observation helps con-
solidate the point that severe microglial disability involves
compromise of both neuroprotective and immunological
(bactericidal) capabilities.
Microglial dystrophy (cytorrhexis) has also been de-
scribed in another experimental model of severe neuro-
pathology induced in rats through administration of the
G-series nerve agent, soman [158]. In this model, micro-
glia undergo extensive fragmentation often in association
with high expression of proinflammatory cytokines, such
as MCP-1 and IL-1 (Figure 11), and the onset of cytor-
rhexis as well as cytokine expression occurs rapidly
within 12 hours after soman exposure. The fact that fea-
tures of microglial degeneration (cytorrhexis) and micro-
glial activation (IL-1 and MCP-1 expression) occur
simultaneously in the same cells underscores the severity
of soman-induced CNS injury and also offers further
support in favor of microglial exhaustion, which in this
case happens on a rather expedited schedule.
Overall, it appears then that microglial dystrophy can be
induced experimentally in laboratory rodents under certain
extreme conditions, such as genetically induced neurode-
generative disease or acute intoxication. Ultrastructural
studies showing severe mitochondrial abnormalities [159]
support the idea that sudden and undue oxidative stress
is a key factor in the development of cytorrhexis, and
thus the animal findings are consistent with the sus-
pected influences thought to trigger microglial degener-
ation in humans. The idea of immune exhaustion, or
microglial burn-out, is a central theme that will require
further study especially since it may lend itself to re-
mediation and therapeutic intervention.
Significance (consequences) of microglial pathology
The study of diseased glial cells and their potential im-
portance for neurodegenerative disease pathogenesis is
in its infancy [160]. Specifically, with regard to microglia
it remains a challenge to reconcile understanding of dis-
eased, truly disabled microglia with that of activated
microglia, the latter having been portrayed as overly ag-
gressive and therefore pathogenic cells. For reasons dis-
cussed in this paper and elsewhere [88,95] it seems quite
unlikely that microglial activation directly causes NFD
through bystander damage, and we are inclined to
believe that NFD happens as a result of gradually waning
microglial neuroprotective abilities brought on in large
part by immunological exhaustion of microglia, which in
turn may depend on multiple factors. Microglia can be
neuroprotective in a number of ways, e.g. through free
Figure 9 Microglia in the spinal cord of SODG93A rats. A-C, double staining for microglia (Iba1) and neurons (NeuN) shows progressive loss of
neurons during symptomatic and end stages of motor neuron disease. Microglial activation during symptomatic disease (B) progresses to
microglial dystrophy at 6 months of age when animals are terminal (C). Panel D shows close-up of fragmented microglia as seen with OX-42
staining (brown color) during end stage disease. A few surviving motoneurons are stained blue with cresyl violet. Scale bars: 100 μm (A-C);
20 μm (D).
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factor production, elimination of debris, and it will be
interesting to determine which neuroprotective function
is most crucial such that that reduction or loss could
lead to NFD. However, rather than loss of a single func-
tion, it is also conceivable and perhaps even more likely
that a generalized weakening in microglial capabilities
below a certain minimal essential level may have to occur
in order for NFD to develop. Since microglial dystrophy
can be induced in animals under certain conditions as
shown here, it seems possible through continued animal
experimentation to uncover what kind of external factors
are most effective in terms of promoting microglial
exhaustion and influencing dystrophy development. These
kinds of experiments may also be able to determine if
indeed NFD develops as a direct result of microglial
degeneration.
Multiple lines of evidence have suggested that amyloid
plaques accumulate and persist because dysfunctional
microglia are unable to remove them [3,56,161-163].
While this is clearly a possibility it does not explain why
microglia should be phagocytically dysfunctional in the
first place especially in young transgenic rodents overex-
pressing APP where there is no a priori reason for such
impairment. Moreover, in human brain there is no evi-
dence showing that microglia are attempting to removesoluble, non-fibrillized Aβ accumulating in diffuse pla-
ques. The lack of amyloid removal may therefore not be
due to impaired phagocytic ability but instead be caused
by toughness and indigestibility and of the amyloid
fibrils resulting in the aforementioned “frustration”
which wears down the cells and contributes to their ex-
haustion together with other factors including naturally
occurring senescence. Thus amyloid accumulation, un-
like NFD development, may not be a consequence of
microglial dysfunction.
Metaphorically speaking microglia are hybrids be-
tween neuroprotective glia and immunocompetent cells
and their functional deterioration plays out in dimin-
ished neuroprotection as well as in decreased immuno-
logical capabilities. The latter is strikingly illustrated in
Figure 10 showing presence of bacteria within the CNS
parenchyma. This is a highly unusual phenomenon sug-
gesting profound immunological impairment. Together
with the coincident presence of MNGCs one thinks of
immune deficiency diseases in humans, notably infec-
tion with the human immunodeficiency virus-1 (HIV-
1), where MNGCs represent a pathological hallmark
and microglial cells themselves are the target of the in-
fectious agent [157,164]. It is reasonable to assume that
the functionality of HIV-infected microglia is severely
compromised in terms of both their neuroprotective
Figure 10 Signs of microglial dysfunction. A, Langhans type giant
cell consisting of fused microglia in the brainstem of a SOD1G93A rat, as
shown by lectin histochemistry (brown color). Note the characteristic
arrangement of nuclei along periphery. B, nidus of bacilli in another
section from the same animal, possibly a reflection of impaired
bactericidal activity of microglia. Cresyl violet stain. Scale bar = 20 μm.
Figure 11 Microglial pathology is evident in rats exposed to nerve agen
cytokines (MCP-1 in A; IL-1α in B) in soman exposed rats. Panel A shows seve
cytoplasm, in the piriform cortex (arrows). MCP-1 immunoreactivity is localized
processes also reveal IL-1α immunoreactivity in their cytoplasm (arrow). These
(cytorrhexis) are thought to represent transitional forms; they were found in the
μm. Images provided by Erik A. Johnson, US Army Medical Research Institute of
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why patients with HIV/AIDS frequently suffer from the
consequences of neurodegeneration, i.e. HIV-associated
dementia, as well as a high incidence of opportunistic
CNS infections, notably toxoplasmosis [165,166].Conclusions
There are aging-related morphological and phenotypic
changes in rodent and human microglia that are con-
sistent with both cell senescence and low-grade activa-
tion. However, it is all but impossible to distinguish
between low-grade neuroinflammatory and senescent
changes and these seemingly contradictory phenomena
are in fact one and the same. Since the focus is on
aging when it comes to AD, it would be wise to stop
using the term neuroinflammation as this is suggestive
of pathology more severe than what really exists, and
therefore potentially misleading. In the context of
aging it makes sense to speak simply of microglial sen-
escence, which in humans progresses to an advanced,
pathological level, called dystrophy, that can be dir-
ectly associated with neurofibrillary degeneration.
Making this purely semantic change from inflamma-
tion to senescence would help eliminate the rather
widespread notion that microglia are aggressive im-
mune effector cells, which is the unfortunate result of
prematurely overinterpreting and extrapolating in vitro
observations, and this has not been helpful for advan-
cing understanding of AD pathogenesis. Microglial
cells are not aggressors; they are victims of free radical
damage like all cells. To help curb the ongoing demen-
tia epidemic a major scientific challenge for the future
will be to find ways of slowing or minimizing micro-
glial senescent degeneration.t. Double immunofluorescent staining for microglia (OX-42) and
re dystrophy of microglia, evident as extensive fragmentation of the cells’
in neurons. In Panel B, OX-42-positive microglia with fragmented
cells showing features of both activation (IL-1) and degeneration
dentate gyrus. Survival time is 12 hours; DAPI counterstain. Scale bar: 50
Chemical Defense (USAMRICD), Aberdeen Proving Ground, MD.
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